Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality
- 20 April 2005
- journal article
- research article
- Published by Elsevier BV in International Journal of Cardiology
- Vol. 100 (2), 253-265
- https://doi.org/10.1016/j.ijcard.2004.08.051
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Recurrence of Left Ventricular Hypertrophy Following Cessation of Erythropoietin TherapyArtificial Organs, 2002
- Pathophysiology of cardiovascular damage in the early renal populationNephrology Dialysis Transplantation, 2001
- The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizationsJournal of the American College of Cardiology, 2000
- Cardiovascular consequences of correction of the anemia of renal failure with erythropoietinKidney International, 1993
- Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietinAmerican Heart Journal, 1992
- Therapy with Recombinant Human Erythropoietin Reduces Cardiac Size and Improves Heart Function in Chronic Hemodialysis PatientsAmerican Journal of Nephrology, 1991
- Impact of left ventricular hypertrophy on survival in end-stage renal diseaseKidney International, 1989
- Population implications of electrocardiographic left ventricular hypertrophyThe American Journal of Cardiology, 1987
- Sudden death: Lessons from subsets in population studiesJournal of the American College of Cardiology, 1985
- Electrocardiographic Left Ventricular Hypertrophy and Risk of Coronary Heart DiseaseAnnals of Internal Medicine, 1970